Posts tagged with 'ma'
Pharma M&A Deal Volume Smallest In YearsRead the rest of this entry »
Vantage is out with a half-year review of developments and trends in pharma, medtech and biotech. The headline is that M&A activity has slowed despite two mega-deals worth a combined $137 billion.
Other deals pushed the total value of takeovers in the first half of the year to $173 billion. The report describes this as " an eye-watering sum that already beats the last three full years on total deal ...
Most Expect Consolidation Of Alt Fund Admin FirmsRead the rest of this entry »
In a dramatic turnabout from a year ago, three-quarters of alternative fund administration firms expect industry consolidation in the near term.
The recently released eVestment Alternative Fund Administration 2018 survey found respondents to the annual survey far more likely now to see net exits to increase than they were in 2017 when 47% foresaw fund administration firm consolidation.
A comment in the report, attributed to a "Global Custody Bank," said: ...
More Layoffs Coming As Pharma Reorg ContinuesMore layoffs in the pharmaceutical industry were announced in the last several days, as the worldwide reorganization of big pharma continues.Read the rest of this entry »
GlaxoSmithKline said it would close a Pittsburgh consumer health unit office, threatening some 275 workers there. The company is planning to consolidate three offices. An unknown number of workers would be given the opportunity to relocate.
Meanwhile the fallout from the Valeant - Actavis takeover fight for Allergan ...
Tech M&A, IPOs Grew 58% In 2014California topped the nation last year in IPOs and M&A in the tech sector, with a reported 523. That was more than the next five markets combined, and triple the number of second place New York.Read the rest of this entry »
The 2014 Global Tech Exits Report, compiled by venture-capital tracker and tech-exits database CB Insights, says there were 2,886 tech exits last year, a 58% increase over 2013. That breaks down to 2,807 ...
Accounting Firm M&A 'Frenzy' to Continue In 2015Read the rest of this entry »
There's little chance of a merger among accounting's Big Four, but the M&A fervor that dominated the industry last year will continue in 2015, only in a different form.
Smaller accounting firms, especially in metro areas, will be the likely targets, as the top 100 firms look to add geographic reach, new niches and acquire talent.
That's a key takeaway from a M&A experts roundtable sponsored by Accounting Today. ...
Crestor Maker Rejects $118 Billion OfferRead the rest of this entry »
Turning its back on $119 billion, U.K.-based AstraZeneca rejected Pfizer’s latest and reportedly final offer for the company. Bloomberg News declared the deal, sweetened more than once, now at a stalemate, with Pfizer (under British law) having a week to decide what to do next. Pfizer's latest bid was made Sunday evening. Hours later, AstraZeneca's board rejected the offer saying it “undervalues the company and its attractive prospects.” Reuters
Botox Maker Allergan Rejects $46 Billion TakeoverRead the rest of this entry »
The Irvine, Calif. maker of anti-wrinkle drug Botox has so far had no luck convincing other pharmaceutical firms to make it an offer it can't refuse so it can convince shareholders to refuse a $45.7 billion acquisition bid from Canadian drug firm Valeant Pharmaceuticals International, Inc.
Despite being rebuffed by Sanofi and John ...
$4.2 Billion Deal Bolsters Shire's Orphan Drug FocusRead the rest of this entry »
Irish drug-maker Shire Plc. is buying ViroPharma for $4.2 billion, giving it access to several drugs targeted at rare diseases. At $50 a share, the deal values the U.S. biopharmaceutical at a heady 58 times EBITDA.
This is Shire's third significant acquisition this year, and is the biggest in the company's history, topping the $3.6 billion it paid in 2001 for Canada's BioChem Pharma Inc.
The price is “clearly ...
Bayer Buys U.S. Vitamin Maker SchiffRead the rest of this entry »
German pharmaceutical maker Bayer AG has bought U.S. vitamin maker Schiff Nutrition for $1.2 billion. The acquisition will give Bayer a big slice of the $35 billion U.S. consumer health market. It's the third acquisition in as many months for Bayer. In August, it bought agricultural chemical and biologics maker AgraQuest for $425 million. Last month it bought Teva Pharmaceuticals Industries animal health group for about $145 million. Schiff has ...
What's Ahead For Hospitals? Four Experts Look At The FutureRead the rest of this entry »
Towers Watson says health care reform is dramatically accelerating the pace and intensity of change in an industry that was already beset by such pressures as skills shortages, financial challenges, and alternative approaches to care.
In four videos, company leaders in research, workforce planning, M&A, and physician compensation in the talents and rewards practice present their views on the challenges facing the hospital industry and what hospitals can do ...